← Leaderboards
Johan Skog
Massachusetts General Hospital
$4,465,208
Attributed
$10,696,078
Total exposure
3
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.3M · FY2018–22$2.5M$1.9M$1.3M$625K$0
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$10,696,078 · 3
By mechanism
U01$7,516,214 · 2
R01$3,179,864 · 1
Top collaborators
- Hakho Lee12 shared
- Bob S Carter5 shared
- Cesar M Castro5 shared
- Daniela M Dinulescu5 shared
Most similar at Massachusetts General Hospital
Same institution · by research overlap
- Hakho Lee$15,122,007
- Hyungsoon Im$5,025,374
- Ralph Weissleder$110,468,710
- John A Parrish$14,847,377
- Cesar M Castro$5,964,176
Others in their field
Other Emerging Leaders on “Variant”
- Yunda Huang · Fred Hutchinson Cancer Center$63,914,632
- Leonard Freedman · Leidos Biomedical Research, Inc.$63,277,106
- Theresa Engel · Leidos Biomedical Research, Inc.$44,839,860
- Scott Topper · Broad Institute, Inc.$40,042,399
- Chris Karlovich · Leidos Biomedical Research, Inc.$38,534,220
- Evan Z Macosko · Broad Institute, Inc.$29,606,858
Research focus
VariantSuccessInnovative TechnologiesMonitorResourcesStandardizationExtracellular VesiclesIndustryMolecularMedical DeviceMultidisciplinaryReproducibilityDiagnosticSamplingAdoptionExosomeCancer CellGeneral HospitalsLiquid BiopsyCancer DiagnosticsMalignant NeoplasmsMassachusettsBaseLaboratories
Grant awards (17)
Liquid Biopsy for treatment stratification of IDH1.R132H and EGFRvIII mutant gliomas$773,953
U01 · FY2022 · CA
Early Detection through Novel OCEAN Technology - Ovarian Cancer Exosomal Analysis with Nanoplasmonics$573,531
U01 · FY2022 · CA
Clinical platform for high-throughput analyses of extracellular vesicles$572,891
R01 · FY2022 · CA
Liquid Biopsy for treatment stratification of IDH1.R132H and EGFRvIII mutant gliomas$808,800
U01 · FY2021 · CA
Early Detection through Novel OCEAN Technology - Ovarian Cancer Exosomal Analysis with Nanoplasmonics$746,693
U01 · FY2021 · CA
Clinical platform for high-throughput analyses of extracellular vesicles$588,778
R01 · FY2021 · CA
Liquid Biopsy for treatment stratification of IDH1.R132H and EGFRvIII mutant gliomas$808,800
U01 · FY2020 · CA
Early Detection through Novel OCEAN Technology - Ovarian Cancer Exosomal Analysis with Nanoplasmonics$746,693
U01 · FY2020 · CA
Clinical platform for high-throughput analyses of extracellular vesicles$702,900
R01 · FY2020 · CA
Liquid Biopsy for treatment stratification of IDH1.R132H and EGFRvIII mutant gliomas$784,536
U01 · FY2019 · CA
Early Detection through Novel OCEAN Technology - Ovarian Cancer Exosomal Analysis with Nanoplasmonics$705,145
U01 · FY2019 · CA
Clinical platform for high-throughput analyses of extracellular vesicles$565,123
R01 · FY2019 · CA
Clinical platform for high-throughput analyses of extracellular vesicles$110,699
R01 · FY2019 · CA
Clinical platform for high-throughput analyses of extracellular vesicles$42,165
R01 · FY2019 · CA
Liquid Biopsy for treatment stratification of IDH1.R132H and EGFRvIII mutant gliomas$808,800
U01 · FY2018 · CA
Early Detection through Novel OCEAN Technology - Ovarian Cancer Exosomal Analysis with Nanoplasmonics$759,263
U01 · FY2018 · CA
Clinical platform for high-throughput analyses of extracellular vesicles$597,308
R01 · FY2018 · CA